Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians

Pharmacogenomics

Volumn 13, Issue 1, 2012, Pages 113-121

  Brown, Kevin C ^a   Hosseinipour, Mina C ^b   Hoskins, Janelle M ^a   Thirumaran, Ranjit K ^c   Tien, Hsiao Chuan ^d   Weigel, Ralf ^c   Tauzie, Jean ^f   Shumba, Ida ^e   Lamba, Jatinder K ^e   Schuetz, Erin G ^b   McLeod, Howard L ^b   Kashuba, Angela Dm ^b   Corbett, Amanda H ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e LIGHTHOUSE TRUST   (Malawi)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CYP2B6; CYP450; Malawi; Nevirapine; Nuclear receptor n P glycoprotein; Pharmacokinetics

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOSINE; DNA; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; PREGNANE X RECEPTOR; THYMINE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGE; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; ETHNIC GROUP; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALAWIAN; MALE; MULTIVARIATE ANALYSIS; NEGRO; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; RACE DIFFERENCE; WILD TYPE;

ADULT; AFRICA SOUTH OF THE SAHARA; ALLELES; ANTI-HIV AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYCLOPHILINS; FEMALE; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID;

EID: 83755183491     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.132     Document Type: Article

References (31)

1. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003). (Pubitemid 36159890)
2. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005). (Pubitemid 43205520)
3. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002). (Pubitemid 34223859)
4. Haas DW, Wu H, Li H et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult aids clinical trials group study. J. Acquir. Immune Defic. Syndr. 34(3), 295-298 (2003). (Pubitemid 37377363)
5. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an adult aids clinical trials group study. AIDS 18(18), 2391-2400 (2004). (Pubitemid 40065906)
6. Klein K, Lang T, Saussele T et al. Genetic variability of CYP2D6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15(12), 861-873 (2005). (Pubitemid 41666768)
7. Penzak SR, Kabuye G, Mugyenyi P et al. Cytochrome p450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8(2), 86-91 (2007). (Pubitemid 46390844)
8. Hosseinipour MC, Corbett AH, Kanyama C et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS 21(1), 59-64 (2007). (Pubitemid 44912537)
9. Corbett AH, Hosseinipour MC, Nyirenda J et al. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Antiviral Ther. 15(1), 83-90 (2010).
10. van Heeswijk RP, Veldkamp AI, Mulder JW et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14(8), F77-F82 (2000). (Pubitemid 30336080)
11. Luzuriaga K, Bryson Y, McSherry G et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J. Infect. Dis. 174(4), 713-721 (1996). (Pubitemid 26325885)
12. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Disp. 27(12), 1488-1495 (1999).
13. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T
14. Saitoh A, Sarles E, Capparelli E et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21(16), 2191-2199 (2007). (Pubitemid 350287217)
15. Ramachandran G, Ramesh K, Hemanth Kumar AK et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J. Antimicrob. Chemother. 63(4), 841-843 (2009).
16. Mahungu T, Smith C, Turner F et al. Cytochrome p450 2B6 516G->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 10(5), 310-317 (2009).
17. Haas DW, Gebretsadik T, Mayo G et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African-Americans. J. Infect. Dis. 199(6), 872-880 (2009).
18. Chantarangsu S, Cressey TR, Mahasirimongkol S et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J. Antimicrob. Chemother. 64(6), 1265-1273 (2009).
19. Faucette SR, Zhang TC, Moore R et al. Relative activation of human pregnane x receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320(1), 72-80 (2007). (Pubitemid 46025721)
20. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Disp. 36(1), 169-181 (2008).
21. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab. 6(4), 369-383 (2005). (Pubitemid 41086769)
22. International HapMap Consortium. The international HapMap project. Nature 426(6968), 789-796 (2003).
23. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J. Chromatog. 791(1-2), 137-147 (2003). (Pubitemid 36638747)
24. Marsh S, King CR, Garsa AA, McLeod HL. Pyrosequencing of clinically relevant polymorphisms. Methods Mol. Biol. (Clifton, NJ) 311, 97-114 (2005).
25. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med. Genet. 6, 19 (2005).
26. Rohrbacher M, Kirchhof A, Geisslinger G, Lötsch J. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics 7(7), 995-1002 (2006). (Pubitemid 44644779)
27. Zackrisson AL, Lindblom B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur. J. Clin. Pharmacol. 59(7), 521-526 (2003). (Pubitemid 37368904)
28. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001). (Pubitemid 32268418)
29. De Vries-Sluijs TE, Dieleman JP, Arts D et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1- infected population. Clin. Pharmacokinetics 42(6), 599-605 (2003). (Pubitemid 36805618)
30. Veldkamp AI, Weverling GJ, Lange JM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15(9), 1089-1095 (2001). (Pubitemid 32549859)
31. Ensom MHH, Blouin RA. Dietary influences on drug disposition. In: Applied Pharmacokinetics and Pharmacodynamics: Principles of therapeutic drug monitoring. Burton ME, Shaw LM, Schentag JJ, Evans WE (Eds). Lippincott Williams and Wilkins, Baltimore, MA, USA, 242-256 (2006).